Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07116824) titled 'HB1801 Combined Treatment of HER2-positive Breast Cancer' on Aug. 7.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Condition:
HER2-positive Breast Cancer
Intervention:
Drug: HB1801
Drug: Trastuzumab
Drug: Pertuzumab
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: September 15, 2025
Target Sample Size: 80
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07116824
Published by HT Digital ...